GALAD Score, Serum
Use
The GALAD score (gender, age, alpha-fetoprotein L3% [AFP-L3], AFP, des-gamma-carboxy prothrombin) model score is used for calculating the risk of hepatocellular carcinoma (HCC) development in patients with chronic liver disease. This model combines the three biomarkers AFP, AFP-L3, and DCP with patient demographic data to provide a more accurate assessment of HCC presence than the use of these markers individually or in combination. It is especially useful in early-stage detection, outperforming traditional ultrasound in diagnostic accuracy.
Special Instructions
The GALAD score is not orderable as an individual test but is part of the Hepatocellular Carcinoma Risk Panel with GALAD Score, Serum (HCCGS).
Limitations
The GALAD score requires accurate acquisition of total AFP and AFP-L3% test values, which must be obtained using the uTASWako i30 analyzer for correct calculation. It should not be interpreted as definitive evidence for the presence or absence of liver malignancy. The results may be unreliable in patients who have developed antibodies to animal proteins. Caution is advised when interpreting results in populations with different HCC prevalence or etiology compared to the cohorts in which the score was originally validated.
New York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 96450-2
- 96450-2
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.25 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial. Preferred container is Serum gel; acceptable is Red top.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 5 days |
| Frozen | 90 days |